Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verizon

Johnson & Johnson reported strong earnings growth last year but its shares only offer a 3% dividend yield at recent prices. Verizon offers a big 6.3% dividend yield at recent prices but its bottom line shrank last year.

Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon

Lowe's

LVMH Moet Hennessy Louis Vuitton

Best Buy

Deutsche Bank

Home Depot

Kenvue

One of the best ways to create wealth is finding the right dividend stocks to buy and hold. No other asset class has performed as well as buying equities, not gold, not bonds, not real estate.

7 Dividend Stocks to Buy and Never Sell: January 2024 Edition

Johnson & Johnson reported strong Q4 FY23 results and reaffirmed guidance for FY24, exceeding expectations. The company's pharmaceutical business has the potential for 5-7% long-term growth, driven by novel therapies and made a strong presence in the oncology market. The MedTech sector is expected to have stable growth, with JNJ's robust procedure growth and product innovation contributing to expansion.

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its role in the opioid addiction crisis.

Washington state reaches nearly $150 million settlement with Johnson & Johnson over opioid crisis

Some investors struggle with owning the shares because of uncertainty over ongoing baby powder lawsuits.

J&J Can't Promise Wall Street No More Tears

Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding quarter in 2022.  The pharmaceutical giant disclosed a net income of $4.13 billion, a rise from the $3.

J&J Sees Surge in MedTech Sales Post-Kenvue Split

General Electric

With the earnings season now in full force, valuable data to gauge the broader economy will be rolling in.

3 Stocks to Consider After Beating Earnings Estimates

The commercial success of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato for use in treatment-resistant depression and major depressive disorder with suicidal ideation bodes well for other psychedelics companies, analysts at Jefferies believe.  When reporting its 4Q results Tuesday, J&J said Spravato sales grew 73% year-over-year to $206 million, implying an $825 million run rate since the product launched five years ago.

J&J's Spravato success confirms commercial viability of psychedelics for mental health

The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.

Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million

Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript

Johnson & Johnson edged out estimates and delivered in-line guidance for 2024. Concerns about legal settlements and competition for drug Stelara seemed to weigh on the stock.

Why Johnson & Johnson Stock Was Pulling Back Today

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.

J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales

D.R. Horton

Procter & Gamble

Pre-market futures are mixed at this hour, coming off two strong trading days as Q4 earnings season begins to hit its stride. The Dow is -0.55% currently, while the S&P 500 and Nasdaq are +0.21% and +0.36%, respectively.

Mixed Q4 Earnings Report

J&J has maintained that its now-discontinued talc products are safe and do not cause cancer. It previously set aside $400 million to resolve state claims.

J&J agrees to pay $700M to settle talc probes in 42 states

Pre-market trading fortunes are mixed for this morning's reportees, including JNJ, PG, GE, MMM and DHI.

Q4 Earnings for J&J, Procter, GE & More

The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Johnson & Johnson on Tuesday said it had reached a tentative settlement to resolve probes by U.S. states into whether it misled consumers about the safety of its talc products, which thousands of lawsuits claim can cause cancer.

J&J agrees to resolve 42 U.S. states' talc investigations

The agreement in principle addresses an investigation brought by more than 40 states into the marketing of its talcum-based baby powder.

Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe

Bristol-Myers

Gilead Sciences

Legend Biotech

Novartis

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

Johnson & Johnson beat fourth-quarter expectations Tuesday, helped by strength from its medtech segment. JNJ stock rose a fraction.

Why J&J's Narrow Fourth-Quarter Beat Is A Blessing For Medtech

New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today's annual earnings call, but slightly undershot with its adjusted earnings results. The company reported a reported 6.5% year-on-year growth in sales of $85.2 billion, but the full-year earnings per share (EPS) depicted a different trend, decreasing by 15.3% to $5.20 a share.

Johnson & Johnson undershoots full-year earnings guidance

Johnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, although ample news supports the stock price over the long term.

Johnson & Johnson's stock price is at a critical turning point

Johnson & Johnson CFO Joseph Wolk said the drugmaker stills expects its cancer treatment Carvykti to reach peak sales of at least $5 billion, despite a new safety warning from the U.S. Food and Drug Administration.

Johnson & Johnson still expects Carvykti to hit at least $5 bln peak sales -CFO

Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.

J&J Q4 earnings narrowly top expectations

Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adjusted per-share earnings came to $2.29, just ahead of the $2.28 FactSet consensus.

News for Johnson & Johnson Stock (JNJ)